Stock Quote
Osiris Therapeutics Inc (OSIR.O) (Consolidated Issue listed on NASDAQ Global Market)
$6.74
4:00pm EST
+1.97%
$6.61
$6.68
94,230
$6.74
$6.45
$21.65
$5.35
0.61
110,509
OSIR.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Friedli, Peter | Chairman of the Board | -- |
| Mills, C. Randall | President, Chief Executive Officer, Director | 1,215,920 |
| Jacoby, Philip | Chief Financial Officer, Vice President - Finance, PAO, Corporate Secretary | 204,106 |
Profile
Osiris Therapeutics, Inc. (Osiris) is a stem cell therapeutic company, focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The Company’s principal biologic drug candidate, Prochymal, is being evaluated in Phase III... Full Description
Company Address
Osiris Therapeutics Inc
7015 Albert Einstein Drive
Columbia MD 21046
P: +1443.5451800
F: +1443.5451701
7015 Albert Einstein Drive
Columbia MD 21046
P: +1443.5451800
F: +1443.5451701
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Johnson & Johnson | $62.84 | -0.05 |
| Abbott Laboratories | $54.49 | +0.41 |
| Biogen Idec Inc. | $46.94 | +0.02 |
| OSIR.O | Industry | |
|---|---|---|
| P/E(TTM) | -- | 13.11 |
| P/S(TTM) | 5.42 | 32.32 |
| ROI(TTM) | -144.62 | 2.21 |
| ROE(TTM) | -- | 3.47 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | -0.19 |
| EPS Est. (Current Year) | -0.31 |
| Total Revenue | $10.58M |
| Net Income | $-6.80M |
| EPS | $-0.21 |
